Life Science executive with an extensive global network adds to already deep leadership team.
(St. Louis, Missouri February 26, 2013) — Gallus BioPharmaceuticals, LLC (Gallus) announced today the appointment of Mr. Shailesh Maingi to its Board of Directors as an independent director.
Gallus is pleased to announce the addition of Shailesh Maingi to its Board of Directors. Shailesh, a life sciences executive with an extensive global network, is CEO of Kineticos Life Sciences, a management consulting practice focused on advising industry leading life sciences organizations. Shailesh also serves on 2 Advisory Boards. Prior to this, Shailesh was VP of business development for pharmaceutical development at Cardinal Health Pharmaceutical Technologies and Services (now Catalent Pharma Solutions) and VP of marketing at Sigma-Aldrich/Supelco. Shailesh obtained a Bachelor of Science in Chemistry at UNC, Chapel Hill, and an MBA (Cum Laude) from the Golden Gate University, San Francisco.
“I am very excited to join the Gallus Board. Gallus has world class operations and an industry leading quality and regulatory track record. I believe that Gallus is well positioned to capitalize on the enormous market opportunities in biopharmaceutical manufacturing” said Shailesh.
“I am delighted to have Shailesh Maingi join our Board. Gallus is building a strong industry recognition for our ability to provide high quality process development, clinical and commercial supplies of biopharmaceuticals and I look forward to this continuing with support from Shailesh who brings great experience to realizing our vision of being the CMO of choice for our industry” said Mark R. Bamforth, President and CEO of Gallus BioPharmaceuticals.
About Gallus BioPharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Missouri, was established in 2010 and acquired a world-class commercial biopharmaceutical manufacturing facility from Johnson & Johnson’s Centocor division in 2011 and transferred a 160- strong workforce. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected and approved by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services: